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ABSTRACT 
Ectodomain shedding at the cell surface is a major mechanism to regulate the extracellular and circulatory 
concentration or the activities of signaling proteins at the plasma membrane. Human meprin ! is a 145-KDa disulfide-
linked homodimeric multi-domain type-I membrane metallopeptidase that sheds membrane-bound cytokines and 
growth factors, thereby contributing to inflammatory diseases, angiogenesis, and tumor progression. In addition, 
amyloid precursor protein (APP) is cleaved at the !-secretase site giving rise to amyloidogenic peptides. We have 
solved the X-ray crystal structure of a major fragment of the meprin ! ectoprotein, the first of a multi-domain 
oligomeric transmembrane sheddase, and of its zymogen. The meprin ! dimer displays a compact shape, whose 
catalytic domain undergoes major rearrangement upon activation, and reveals an exosite and a sugar-rich channel, both 
of which possibly engage in substrate binding. A plausible structure-derived working mechanism suggests that 
substrates such as APP are shed close to the plasma membrane surface following an “N-like” chain trace. 
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INTRODUCTION 
Physiological processes in the extracellular milieu and the circulation require finely tuned concentrations of 
signal molecules such as cytokines, growth factors, receptors, adhesion molecules, and peptidases. Many of these 
proteins are synthesized as type-I membrane protein variants or precursors consisting of a glycosylated N-terminal 
ectoprotein, a transmembrane helix, and a C-terminal cytosolic tail. Their localization at the cell surface restricts their 
field of action to autocrine or juxtacrine processes. However, to act at a distance in paracrine, synaptic, or endocrine 
events, they have to be released from the plasma membrane into the extracellular space as soluble factors through 
“protein ectodomain shedding” (1, 2). This entails limited proteolysis and is a major post-translational regulation 
mechanism that affects 2–4% of the proteins on the cell surface, occurs at or near the plasma membrane (3), and 
apparently follows a common release mechanism (2). It may also proteolytically inactivate proteins in order to 
terminate their function on the cell surface (4). Peptidases engaged in such processing are “sheddases” and the most 
studied transmembrane sheddases are members of the adamalysin/ADAMs (4, 5) and matrix-metalloproteinase (MMP; 
(6)) families within the metzincin clan of metallopeptidases (MPs; (7-9)). These include ADAM-8, -9,-10,-12, -15, -17, 
-19, -28, and -33 (1, 4); and membrane-type 1 (MT1)-MMP, MT3-MMP, and MT5-MMP (2, 6, 10). Other confirmed 
transmembrane sheddases are the aspartic proteinases BACE-1 and -2 (see (11) and references therein), and the 
malarian parasite serine proteinases, PfSUB2, PfROM1 and PfROM4 (12). Distinct sheddases may participate in 
intercalating processes, with disparate physiological consequences: ADAM-9, -10 ("-secretases), and -17 contribute to 
the non-amyloidogenic pathway of human amyloid precursor protein (APP) processing, while BACE-1 (!-secretase) 
participates in the amyloidogenic pathway. While the former generates innocuous peptides, the latter gives rise to the 
toxic !-amyloid peptides believed to be responsible for Alzheimer’s disease (11). In several instances, shedding at the 
membrane surface is followed by a “regulated intramembrane proteolysis” step within the membrane (1). This is the 
case for the processing of Notch ligand Delta1 and of APP, both carried out by #-secretase after action of an "/!-
secretase (11), and for signal-peptide peptidase, which removes remnants of the secretory protein translocation from 
the endoplasmic membrane (13).  
Recently, human meprin ! (M!) was found to specifically process APP in vivo, which may contribute to 
Alzheimer’s disease (14, 15). It was also reported to activate cell-anchored "-secretase ADAM-10 and to be widely 
expressed in brain, intestine, kidney and skin (14, 16-18). Disruption of M! in mice affects embryonic viability, birth 
weight, and renal gene expression profiles (19). The enzyme was further identified as a sheddase or proteolytic 
regulator at the plasma membrane of interleukin-1! (20), interleukin-18 (21), tumor growth factor " (22), pro-collagen 
III (23), epithelial sodium channel (24), E-cadherin (25), tenascin-C (26), and vascular endothelial growth factor A 
(27). Further substrates include fibroblast growth factor 19 and connective tissue growth factor. Altered expression and 
activity of the enzyme is associated with pathological conditions such as inflammatory bowel disease (28), tumor 
progression (29), nephritis (30) and fibrosis (23). 
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M! is a 679-residue secreted multi-domain type-I membrane MP that belongs to the astacin family within the 
metzincins (7, 9, 16, 31, 32). The enzyme is glycosylated and assembles into either disulfide-linked homodimers or 
heterodimers with the closely-related meprin " subunit (33). M! homodimers are essentially membrane-bound but may 
also be shed from the surface by ADAM-10 and -17 (34, 35). To assess function, working mechanism and activation of 
M!, we analyzed the structure of the major ectoprotein of mature M! (M!$C) and of its zymogen, pro-meprin ! 
(pM!$C). With regard to transmembrane sheddases, to date only the structures of the isolated monomeric catalytic 
domains of ADAM-17 (Protein Data Bank [PDB] access code 1BKC), ADAM-33 (PDB 1R55), MT1-MMP (PDB 
1BUV), MT3-MMP (PDB 1RM8), BACE-1 (PDB 1FKN) and BACE-2 (PDB 2EWY) have been described. 
Accordingly, this is the first structural report of a multi-domain oligomeric transmembrane sheddase. This has allowed 
us a better understanding of the structural basis for latency and activation of this MP and to derive a plausible working 
mechanism for shedding of glycosylated type-I membrane substrates such as APP at the extracellular membrane 
surface. 
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RESULTS AND DISCUSSION 
 
Multi-domain structure of pro-meprin !   – We solved the crystal structures of pM!$C (with two molecules in 
the asymmetric unit) and M!$C (with one molecule; see Supp. Information and Supp.Table S1). The pM!$C 
monomer has overall dimensions of 80!60!70Å (Fig. 1a-c) and a four-domain architecture (Supp.Fig. S2a, b) 
spanning an N-terminal propeptide (PD; T23/E25-R61; M! residue numbering as superindices according to UniProt 
Q16820), a catalytic MP domain (CD; N62-L259), a MAM domain (S260-C427), and a C-terminal TRAF domain (P428-
S593/Q597). The polypeptide starts on the front surface of TRAF (Fig. 1a, c) with the first PD residues facing bulk 
solvent. From E25 to D30, which includes a conserved segment among meprins (F27DVD30), the polypeptide progresses 
right-to-left along the TRAF surface in a nearly extended conformation and includes strand !1 (Fig. 1c; see Supp.Fig. 
1a, b for nomenclature and extent of regular secondary structure elements), which is engaged in a parallel !-ribbon 
interaction with TRAF strand !29. In addition, F27 leans towards a hydrophobic pocket generated by Y557, F532, and M524 
of TRAF; D28 interacts with S560; V29 with Y557 and R516; and D30 with both R516 and R146, the latter from CD. TRAF 
residues Y476, H478, and A561 further contribute to binding. This interaction of the N-terminal segment of PD with 
TRAF, which buries ~460Å2, reveals a novel potential exosite on the TRAF surface that would affect genuine 
substrates at sub-sites P7’-P10’ when bound at the active-site cleft in reverse orientation to PD (see next and penultimate 
chapters). Indeed, these positions are conserved among physiological substrates (36). An example is APP, which is 
cleaved by M! at the !-secretase site (M671-D672; APP residue numbers as subindices according to UniProt P05067) in 
vivo and in vitro to generate amyloidogenic A!42 and A!41 peptides (14, 15). This entails that upon Michaelis-
complex formation, APP segment D672AEFRHDSGYE682 occupies substrate positions P1’-P11’. The tyrosine in P10’ 
would spatially overlap with PD residue F27; serine in P8’ with V29; and aspartate in P7’ with D30. Generally, exosites 
distal from the cleavage site contribute to efficient cleavage and have been previously reported for other peptidases 
such as thrombin (37) and  ADAM family members (38). 
Zymogenic determinants in pro-meprin !  – At V29 of PD, the chain sharply kinks downwards and runs 
vertically until G32 (Fig. 1c). Here, the chain turns again and progresses horizontally at G32-D36 to approach CD. From 
there on, the protein folds across the front surface of CD in reverse orientation to a substrate, thus blocking the cleft. 
This segment includes a helix ("1) perpendicular to the cleft. Altogether, the interaction of PD with CD buries an 
interface of ~1,225Å2 and includes three salt bridges on the prime-side of the cleft (D30- R146 and D34-R146) and two 
more on the non-prime-side (R54-E137 and D56-R131). A loop in the central part of the segment enables D52 to chelate in a 
bidentate manner the catalytic zinc ion from above (Supp.Fig. S1c). In the zymogen, this residue replaces the catalytic 
solvent molecule of mature astacins following an “aspartate-switch” mechanism (39). At R57, the chain turns down and 
reaches the final maturation point of pM!, R61-N62. The first residue of CD is buried in the zymogen in an internal 
cavity framed by F49 and I53 of PD, and W161 and Y191 of CD, and its side chain interacts with E50 and S165. Overall, the 
fold of PD is reminiscent of that of the propeptide of astacin except that in the latter the N-terminus is anchored to the 
catalytic moiety (in the absence of further domains) and helix "1 is rotated by ~70º around a vertical axis so that it 
rather parallels the active-site cleft (PDB 3LQ0; (39)). This means that the PDs of the two structures are only 
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superposable at F49EGDIKLD56 (F18PEGDIKLR25P in pro-astacin; see (39)), which includes the zinc-binding aspartate. 
This is consistent with sequence similarity among PDs of general astacin family members being restricted to a short 
consensus sequence, FXGD (X stands for any residue; (32)). The short PD of M! and other astacins contrasts with the 
large pro-segments found in ADAMs, which actually constitute separate domains capable of inhibiting the CDs in 
trans (40). 
The catalytic domain in pro-meprin !  – The 198-residue CD is a compact ellipsoid reminiscent of a pac-man 
(Supp.Fig. S1a, b). A deep and narrow active-site cleft, which harbors the catalytic zinc ion at mid-width (Supp.Fig. 
1c), separates an upper N-terminal and a lower C-terminal sub-domain (NTS and CTS, respectively) of similar size 
when viewed in standard orientation (Supp.Fig. S1a; (41)). CD is cross-linked by two disulfide bonds within the NTS: 
C103-C255 connects the C-terminus of the domain with a loop, which links helix "2 and strand !3 (L"2!3) and C124-C144 
connects !5 with L!6"3 and contributes thus to shaping the upper-rim of the active-site cleft on its prime side. NTS 
harbors a central twisted five-stranded !-sheet (!2-!6) whose lowermost and only antiparallel strand (!5) shapes the 
upper-rim of the active-site cleft. The sheet is decorated on its concave bottom by two helices, the “backing helix” ("2) 
and the “active-site helix” ("3), which run nearly parallel to the strands of the sheet. Helix "3 includes the first part of 
a long zinc-binding consensus sequence, H152EXXHXXGXXH162 (Supp.Fig. S1c), which is found in astacins but also 
metzincins in general (7-9, 42, 43). This helix ends at G159, which allows for a sharp turn of the polypeptide chain in 
order to enter CTS. The latter contains the third zinc-binding residue, H162, and the “family-specific” residue of 
astacins, E163 (43, 44). Also typical for astacins and metzincins, a tight 1,4-!-type “Met-turn” is located below the 
catalytic zinc-site featuring a strictly conserved methionine, M209 (Supp.Fig. S1c)(8, 45). The rest of CTS has little 
regular secondary structure further to the major “C-terminal helix” ("4; Supp.Fig. S1a, b). Of particular interest is that 
the polypeptide chain is disordered at Y191/D194-S198/L199. This segment corresponds to the “activation domain” in 
astacins (39). 
The MAM and TRAF domains in pro-meprin !  – After CD, the polypeptide chain enters the 168-residue 
MAM domain, which lies behind TRAF and performs no contact with the MP moiety with the exception of some 
residues near the inter-domain junction (Fig. 1a, right). MAM is a !-sandwich consisting of two five-stranded 
antiparallel !-sheets rotated away from each other by ~25º. The sandwich consists of a front sheet twisted by ~70º 
(!10-!13-!18-!15-!16; see Supp.Fig. S1a, b, center) and a back sheet twisted by ~40º and curled (!11-!9+!12-!19-
!14-!17), whose second strand (!9+!12) is interrupted by 310-helix %3 and strands !10 and !11. Overall, the !-
sandwich is built following a “jelly-roll” architecture made up of two four-stranded Greek-key motifs (Supp.Fig. S1b, 
center, in red and magenta, respectively), in which the second motif is inserted after the first !-ribbon (!9+!12-!13) of 
the first motif. The jelly roll is decorated by the aforementioned insertion (Supp.Fig. S1b, center, in pink), which 
includes L!10!11–partially undefined in one of the two molecules in the asymmetric unit–and L!11!12, the 
“dimerization loop” (see below). In addition, the pairs C265-C273 and C340-C427 are at adequate distance and geometry for 
disulfide bonding but, contrary to the SS-bonds in CD, the respective S# atoms are 2.9Å apart. We attribute this to a 
radiation-damage artifact due to the long exposure time required to collect a complete dataset in space group P1. In 
addition, the %3-!10-!11 insertion contributes to an octahedral cation-binding site tentatively interpreted as a sodium 
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site. The ion is coordinated by the side chains of E268, D298, S300, D418, and the main-chain oxygen atoms of S266 and F310 
(Supp.Fig. S1d). Overall, the topology and architecture of this domain is reminiscent of receptor-type tyrosine-protein 
phosphatase µ (PDB 2V5Y), which belongs to the MAM protein family of adhesive proteins initially identified by 
bioinformatic searches in meprin " and !, A5 protein, and receptor protein tyrosine phosphatase µ (46). In particular, 
the MAM domain of tyrosine phosphatase µ was shown to play a major role in homodimerization of the phosphatase 
ectoprotein and in cell adhesion (47).  
Downstream of MAM, the 170-residue TRAF domain interacts with the former burying an interface of ~650Å2 
(Fig. 1a, right). TRAF also interacts with CD through a surface spanning ~950Å2 in one protomer and ~1170Å2 in the 
other as the polypeptide chain could be traced for four residues more in the latter. TRAF features the second type of 
all-! structure found in pM! (Supp.Fig. S1a,b, right), with a five-stranded front sheet (!21-!22-!23-!29-!28) and a 
four-stranded back antiparallel sheet (!20-!30-!24-!25) rotated by ~40º against each other and arranged in a !-
sandwich as in MAM. The front sheet is twisted by ~50º, arched and curled, while the back sheet is just twisted by 
~50º. Altogether, the strands are arranged as two Greek-key motifs (Supp.Fig. S1b, right, in purple and violet), in 
which the second one is inserted between strands #3 (!30) and #4 (!23) of the first one instead of after the first !-
ribbon as in MAM (see above). Again contrary to MAM, which features a jelly roll with parallel Greek keys, in TRAF 
the second Greek key is rotated by ~180º relative to the first one around an axis perpendicular to the plane of the !-
sheets. In TRAF, the double Greek key is decorated with a !-ribbon (!26-!27) after !25, an additional short strand 
(!28) for the front sheet, and a helix ("5) between !29 and !30 (all in blue in Supp.Fig. S1b, right). The only cysteine 
found in this domain, C492, is buried and unbound, and the C-terminus of the molecule (S593/Q597) protrudes from the top 
surface of the monomer (Fig. 1a, left). Overall, M! TRAF is structurally similar to tumor-necrosis factor receptor-
associated factors 2, 3, and 6 (e.g. PDB 1LB5). These gave rise to the TRAF family, which comprises major mediators 
of cell activation engaged in homo- and hetero-dimerization (48). 
Glycosylation sites and “sugar channel” – The pM!$C and M!$C structures contained sugar moieties 
attached to residues N218 and N254 of CTS; N370 of MAM; and N436, N445, N547, and N592 of TRAF. The observed N-
glycosylation patterns, which are consistent with those found in other recombinant proteins produced in Trichoplusia ni 
insect cells (49), are similar to those found in mammalian glycosylation pathways (50) (see Supp.Fig. S2). 
Accordingly, it is assumed that the glycosylations, which were able to be modeled to up to ten hexose moieties at a 
single site (N547) and a maximum of 26 hexoses per protein monomer (see Supp.Fig. S1b for details), represent a bona 
fide mimic of the authentic glycosylation pattern of the enzyme. While the sugar moieties attached to N218 and N254 
point to the bulk solvent and are isolated in the monomer structure, those of the remaining five sites are all oriented 
toward the inter-domain space between MAM and TRAF, although they do not contact each other (Fig. 1a, right). 
Given this accumulation, we termed the lumen between MAM and TRAF “sugar channel”. 
Dimerization of pro-meprin !  – Two pM!$C monomers associate to form a compact ellipsoid with 
dimensions of 115!65!90Å burying an interface of ~1,220Å2 (4.5% of the total monomer surface; Fig. 1d, e). 
Superposition of the whole monomers (rmsd of 0.84Å for 548 common C" atoms) reveals that while PDs, NTSs, and 
TRAFs perfectly fit together, slight deviations are observed for CTSs and MAMs, which lead to displacements of up to 
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2.8Å (measured at S182 C") and 2.6Å (at A410 C"), respectively. Dimerization occurs through nearly symmetric 
interactions between CD of one monomer and MAM of the other. Segments involved include the beginning of !2, 310-
helix %1, L%2!8, the sugar moiety attached to N254, and the C-terminal tail of CD; and L!9%3, %3, L%3!10, !13, 
L!13!14, and !18 of MAM. This is consistent with the general oligomerization and protein-protein interaction 
function of MAM domains (see above). Notably, the dimerization loop of both polypeptide chains point into the center 
of the particle. They are disordered at segment M302-Q306/G307, which includes residue C305. This residue is engaged in 
an inter-molecular disulfide bond cross-linking the dimer as shown by non-reducing SDS-PAGE of carefully washed 
and dissolved crystals, thus suggesting a function as a double safeguard rather than a feature indispensable for 
dimerization. In the particle, the glycans attached at N254 of each monomer interact with each other and contribute thus 
to a small hydrophilic cluster on the surface (see below). Moreover, the two CDs (with their attached PDs), as well as 
the sugar channels, are accessible at opposite ends of the particle, which is consistent with a competent conformation 
for substrate binding (Fig. 1d, right), and both C-termini of the dimer are located on the same face of the particle (Fig. 
1d,e). Given that the complete ectoprotein only comprises a further ~60 residues, which mainly contribute to a compact 
EGF domain (C608-C643) before the transmembrane anchor (I653-V673), this face is likely to be membrane-proximal and 
this allowed us to orient the particle with respect to the extracellular plasma membrane surface (Fig. 1d, left). Further 
evidence for the consistency of this orientation is based on the proximity of the CDs and their active-site clefts to the 
membrane surface, which is required if membrane-anchored substrates are to be cleaved close to the membrane. 
Activation to mature meprin !  – Activation of meprins requires proteolysis of the N-terminal PD, which is 
catalyzed by trypsin in the intestinal lumen and kallikrein-related peptidases (KLK-4, -5 and -8) in other tissues (17, 
51). Comparison of the zymogenic and mature structures, which were obtained in different crystal forms, reveals that 
in general the dimers (established in M!$C between symmetry equivalents) fit together with a global rmsd of 1.2Å for 
1,006 common C" atoms (out of 561+554 residues in pM!$C and 533+533 in M!$C; Supp.Fig. S3a). Detailed 
inspection, however, shows that CTSs undergo major rearrangement upon maturation through a hinge rotation of ~25º 
towards the cleft around E163, H210, and G236, which entails a maximum displacement of ~8Å (at G183 C"; see Supp.Fig. 
S3b-d). In this way, the space exposed by PD removal is subsequently occupied in part by CTS. This closing hinge 
motion further causes displacement of the mature N-terminus of M! and a rotation of its first three residues by ~180º. 
Thus, N62 becomes completely buried inside the mature CD moiety and hydrogen-bonded through its N&2 atom to the 
side chain of the family-specific residue E163. The latter has the same side-chain conformation as in the zymogen and is 
likewise bound to K248 through a buried salt bridge. Maturation further entails rigidification of the formerly flexible 
activation segment (see above) and its upwards shift towards the cleft by ~4Å (at Y191 C"). This leads to a competent 
conformation that enables D197O and S196O# to bind the "-amino group of N62 (Supp.Fig. S3c,d). The stiffening of CD 
contributes to the traceability of M!$C structure along its entire polypeptide chain (N62-T594). This holds true also for 
the flexible loop L!11!12, which encompasses the inter-molecular disulfide bond, although this is based on weak 
electron density. A further key role in CTS rearrangement is played by W161, whose side chain rotates by ~180º around 
its '2 angle and becomes sandwiched by the ascending side chain of Y191 of the activation segment. Overall, the major 
rearrangement observed is compatible with the gross particle structure, indicating that the zymogen is already in a 
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preformed conformation adequate for catalysis, which requires only a rigid-body rearrangement of a sub-domain 
spanning 1/7 of the full-length protein for full competence.  
Maturation also constricts the active-site cleft and this affects the side chain of Y211, which is engaged in zinc 
and substrate binding, and catalysis in mature astacin CDs (i.e. the “tyrosine-switch” residue; (52)) and some other 
metzincins such as serralysins and pappalysins (8). In the zymogen, it is pulled away from its competent position by the 
intercalation of PD helix "1, in particular the side chains of I37-F38 (Fig. 1b), and removal of PD allows Y211 to 
approach the catalytic ion (replaced in the M!$C structure with a cadmium; see Supp. Information). There is additional 
electron density on the prime-side of the active-site cleft of the mature enzyme–potentially corresponding to a substrate 
or inhibitor with low occupancy, which was conservatively interpreted as a glycerol molecule. Most noteworthy, R238, 
engaged in a salt bridge with D36 in the zymogen (see above), becomes reoriented with regard to its side chain and 
occupies the space of D36-I37 of PD. This arginine is found within a segment mainly engaged in shaping the S1’ pocket 
in astacins, the “170-loop” (32), and in M! it accounts for its preference for acidic residues in this sub-site (see 
Supp.Fig. S3 and (36)). Further inspection of the active-site cleft and the adjacent exosite provided by TRAF (see first 
chapter) reveals that R146 and R516 (to the right of R238 in Fig. 1b,c), and R184 from L!7%2 of CD, which interacts with 
E42 in the zymogen and becomes reoriented upon maturation (Supp.Fig. S3b-d), could explain the preference of M! for 
acidic side chains also in downstream prime-side sub-sites (see first chapter), pinpointing a unique cleavage specificity 
among extracellular proteases (36).  
Finally, the substrate specificity of M! is complementary to that of other physiologically relevant 
transmembrane sheddases. The most studied ones, ADAM-17, ADAM-10, and MT1-MMP, as well as other ADAM 
and MMP family members, have specificity for large and medium-sized hydrophobic residues in P1’ as found, for 
example, in ADAM-17 substrates (53) and the "-secretase site of APP (K687-L688). BACE-2 also cleaves at the "-
secretase site (54). Accordingly, M! would be the only transmembrane sheddase capable of cleaving before acidic 
residues in general and at the !-secretase site of APP in particular in addition to BACE-1 (15). 
A working mechanism for shedding at the plasma membrane – The structures of both pM!$C and M!$C 
reveal a dimer with a membrane-proximal face (see above). We constructed a homology model for the remaining ~60 
residues of the ectoprotein–mainly encompassing an EGF-like domain–, the 20-residue transmembrane anchor, and the 
27-residue cytosolic tail of each monomer (see Supp. Information), which enabled us to propose a molecular 
mechanism for M!-mediated shedding at the plasma membrane (Fig. 2). This is visualized utilizing a tentative model 
for APP region F624-L723, which includes the final segment of the ectoprotein and the transmembrane helix (55) and, 
thus, the !-secretase cleavage site (see first chapter). Following this model, a substrate chain would be bound at the 
membrane-distal part (F624-V640 of APP) by the sugar channel of M! monomer one, whose two major glycosylations at 
N547 of MAM and N370 of TRAF would act like a bat-winged saloon door to admit and retain the substrate chain. This 
would be consistent with the general function of such domains in protein-protein interactions. Downstream, the 
substrate chain would run along the back surface of the cognate CD until position L650 to approach the interface 
between CDs within the dimer and, eventually, enter the active-site cleft of M! monomer two (Fig. 2). An intra-
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molecular mechanism involving all three domains of one monomer is unlikely as the substrate would have to undergo a 
long excursion after passing through the sugar channel and the back surface of the cognate CD to reach its active-site 
cleft with the correct N-to-C polarization (Fig. 1e). The first residue after the !-secretase cleavage site, D672, would be 
located in the S1’ pocket of M!, thus matching its substrate specificity. Further downstream sub-sites of the substrate 
would run across the cleft and the prime-site exosite on the TRAF surface (see first chapter) of M! monomer two and 
then turn down to reach the APP transmembrane segment at G700. Generally, the substrate would follow an “N-like” 
trajectory (Fig. 2 top right) and involve domains from both monomers within the M!-dimer. In addition, this 
mechanism would be sugar-assisted. The majority of potential shedding substrates (87% of single-pass transmembrane 
proteins; (56)) are glycosylated, and this holds true also for APP and other M! substrates. In particular, APP is 
glycosylated at T633, T651, T652, T659, T663, S667, and Y681 with regard to the segment under inspection here (57). Of these 
sites, the proposed model predicts that the latter three could be at or close to sub-sites P5, P7, and P10’, i.e. they would 
not interact with the enzyme but rather solvent exposed. By contrast, the glycans attached to T651, T652, and T659 could 
potentially interact with the site created by the symmetric N254 glycosylations of M!, and the one at T633 with that of 
M! N436 (Fig. 2). Overall, this mechanism would be compatible with other type-I transmembrane substrates that are 
shed at sites at least 20-25 residues above the membrane. The different N-glycans found on the surface of the M! 
particle along the proposed substrate path (see Fig. 2) could provide alternative anchor points for the particular sugar 
moieties of each substrate. 
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MATERIALS AND METHODS 
 
A detailed description of procedures is provided under Supp. Information. Briefly, pM!$C was produced by 
recombinant baculovirus-induced overexpression in insect cells and activated by trypsin as reported (58). The structure 
of pM!$C was solved by a combination of single-wavelength anomalous diffraction and Patterson search. The 
structure of M!$C was solved by Patterson search. A model for full-length M! was obtained by connecting a 
homology model for the EGF-like domain with the experimental structure and a modeled transmembrane helix plus 
cytosolic tail by linkers of stereochemically reasonable conformation. 
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FIGURE LEGENDS  
Figure 1 – Structure of pro-meprin ! . (A) The structure of the pM!$C monomer shown in front (left panel; 
CD in standard orientation according to (41)) and top (right panel) reference views. The latter is along the sugar 
channel (green arrow). Glycans are depicted as stick models and the respective asparagine residues are numbered. The 
corresponding surface models are depicted above each picture (glycans in white). PD is shown in ochre, CD in 
aquamarine, MAM in red, and TRAF in purple. The zinc and the sodium ions are shown as magenta and blue spheres, 
respectively. (B) Close-up view in stereo of (A), left panel, to highlight residues engaged in PD-CD interactions. (C) 
Same as (B) in mono for the interaction between PD and TRAF. The first two residues of the structure (P23-W24) are 
actually T23-P24 in the natural protein (see Supp. Information). (D) pM!$C dimer superposed with its Connolly surface 
shown in the front (left panel; in a plane with the membrane) and bottom (right panel) dimer reference views. PDs are 
shown in ochre and yellow, CDs in aquamarine and blue, MAMs in red and green, TRAFs in purple and pink, and 
sugar moieties in white and gray. The intermolecular twofold axis is shown in red and green arrows point at the sugar 
channels. (E) Cartoon depicting the dimer as a ribbon in front (left panel) and bottom (right panel) views as in (D). 
Green arrows run along the sugar channels and a pink arrow highlights the cleft of one CD with the adequate 
orientation of a substrate. The segment containing the inter-molecular disulfide bond between C305 residues is 
disordered in the zymogen and its approximate position is highlighted by orange ellipses.  
Figure 2 – Sheddase mechanism of meprin ! . Working model of M! function based on the experimental 
dimer (CDs in aquamarine and turquoise, MAMs in orange and red, TRAFs in mauve and purple, and glycosylation 
moieties in light green) in front (top panel) view (see Fig. 1d, left) and top (from the membrane surface; bottom panel) 
view from the membrane (here the membrane was removed for clarity). The segments present in the M! dimer but 
missing in the experimental M!$C structure (EGF, transmembrane (TM), and cytosolic tail (CST)) have been 
computationally modeled (see Supp. Information) and are shown in white/light blue. A transmembrane substrate model 
for APP (segment 624-723) is shown as a blue ribbon. The substrate segment proposed to interact with the dimer 
partner is depicted in pale blue to highlight that this part of the mechanism is more speculative. APP glycosylation sites 
relevant for the proposed mechanism are marked in yellow on the ribbon and labeled. In the top image, red ellipses 
highlight sugars attached to N436 of the right monomer (bottom ellipse) and to N254 of both monomers (top ellipse). The 
bottom image only shows the latter ellipse. Top right insert, a possible “N-like” trajectory of the substrate. 
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SUPPORTING INFORMATION 
 
1. EXPERIMENTAL PROCEDURES 
Protein production — The pro-meprin ! ectomoiety lacking the N-terminal signal peptide and the C-terminal 
87 residues (numbering according to the pre-pro-sequence, UniProt Q16820), hereafter referred to as pM!"C, was 
produced by recombinant baculovirus-induced overexpression in Trichoplusia ni insect cells and activated by trypsin to 
yield mature meprin ! (M!"C) as reported (1). In the expression construct T23-P24 were replaced with P23-W24. 
Crystallization and structure solution — Crystallization assays were performed by the sitting-drop vapor 
diffusion method. Reservoir solutions were prepared by a Tecan robot and 100-nL crystallization drops were dispensed 
on 96x2-well MRC plates (Innovadyne) by a Phoenix nanodrop robot (Art Robbins) at the High-Throughput 
Crystallography Platform (PAC) of the Barcelona Science Park. Plates were stored in Bruker steady-temperature 
crystal farms at 4°C and 20ºC. Successful conditions were scaled up to the microliter range with 24-well Cryschem 
crystallization dishes (Hampton Research). pM!"C at ~7.0mg/mL in 20mM HEPES pH7.5 was crystallized at 20ºC 
from equivolumetric drops with 18.2% polyethylene glycol 8,000; 1M LiCl; 0.1M bicine pH9.0 as reservoir solution. 
M!"C at ~6.8mg/mL in 20mM HEPES pH7.5; 1mM phenylmethylsulfonyl fluoride; 100µM actinonin was 
crystallized using 20% polyethylene glycol 3,350; 0.2M sodium malonate; 0.1M bis-tris propane pH8.5 as reservoir 
solution, and 0.1M CdCl2 as an additive. Crystals were cryo-protected by immersion in harvesting solutions (25% 
polyethylene glycol 3,350; 1M LiCl; 0.1M bicine pH9.0 for pM!"C; 25% polyethylene glycol 3,350; 0.2M sodium 
malonate; 0.1M bis-tris propane pH8.5 for M!"C) supplemented stepwise with glycerol (0-15% for pM!"C; 0-20% 
for M!"C). Complete diffraction datasets were collected from liquid-N2 flash-cryo-cooled crystals at 100K (provided 
by an Oxford Cryosystems 700 series cryostream) on a ADSC Q315R CCD and a Pilatus 6M pixel detector at beam 
lines ID23-1 (pM!"C) and ID29 (M!"C), respectively, of the European Synchrotron Radiation Facility (ESRF, 
Grenoble, France) within the Block Allocation Group "BAG Barcelona.” Crystals were triclinic (pM!"C) and 
hexagonal (M!"C), with two and one molecules per asymmetric unit, respectively. Diffraction data were integrated, 
scaled, merged, and reduced with programs XDS (2) and SCALA (3) within the CCP4 suite of programs (4) (see 
Supp.Table S1).  
The structure of pM!"C was solved by a combination of single-wavelength anomalous diffraction and Patterson 
search. The latter was performed with program PHASER (5) with the structure of crayfish pro-astacin (PDB 3LQ0; 
(6)), adequately trimmed and modified for its side chains with program CHAINSAW (7), as searching model for the 
catalytic domain and part of the pro-segment; this gave two unambiguous solutions with space group P1. Diffraction 
data to 2Å resolution of a crystal collected at the zinc K-edge peak wavelength, as inferred from a previous XANES 
fluorescence scan, enabled program SHELXD (8) to independently identify the two zinc sites of the dimer present in 
the asymmetric unit. Subsequent phasing with these two sites using program SHELXE and higher-resolved diffraction 
data to 1.85Å resolution as a pseudo-native dataset, combined with the calculated phases of the two Patterson-search 
solutions, yielded a suitable electron density map for chain tracing on a Silicon Graphics Octane2 Workstation using 
program TURBO-FRODO (9). Model building of the four domains–propeptide (PD), catalytic domain (CD), MAM 
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domain, and TRAF domain–of the two molecules alternated with crystallographic refinement with program 
BUSTER/TNT (10), which included TLS refinement and, initially, NCS restraints, until completion of the model. The 
final model of pM!"C comprised residues 25-193+200-301+308-597 of molecule A and 23-190+199-277+282-
301+307-593 of molecule B. Out of the ten cysteine residues of the sequence, four made two disulfide bonds in the CD 
(C103-C255 and C124-C144); two more pairs of MAM (C265-C273 and C340-C427) were at adequate distance for disulfide 
bonding but were unbound, probably due to a radiation-damage artifact resulting from the long exposure time required 
to collect a complete dataset in space group P1; C305 of MAM was in a flexible segment but was engaged in an inter-
molecular disulfide bond as revealed by non-reducing SDS PAGE; and C492 of TRAF was unpaired.  In addition, each 
protomer contained a zinc and a (tentative) sodium cation. N-linked glycosylations were found attached to residues 
218, 254, 370, 436, 445, and 547 of each monomer. These comprised 10(10) N-acetylglucosamine, 8(7) #-D-mannose, 
3(5) #-L-fucose, and 4(2) !-D-mannose moieties in total for monomer A (monomer B) according to the overall scheme 
depicted in Suppl.Fig. S2. Five tentative chloride ions, one glycerol molecule, and 808 solvent molecules completed 
the model.  
The structure of M!"C was solved by Patterson search with program PHASER. Each of the three domains 
shared with the zymogen was used as an independent searching model. Model completion and refinement with 
BUSTER/TNT proceeded as aforementioned except that structurally equivalent parts of the higher-resolved zymogen 
structure were used to restrain refinement of the low-resolution mature enzyme structure. The final model of 
M!"C comprised residues 62-594 of the single crystallographically-independent molecule (monomer A) plus a 
glycerol molecule bound to the active-site cleft, a (tentative) sodium cation (by analogy with the zymogen structure) 
and a (tentative) cadmium replacing the catalytic zinc, which was assigned based on electron-density maps, 
approximate distances to the protein ligands, and its presence in the crystallization conditions. The intermediate MAM 
domain is less well defined by electron density than the flanking ones, as revealed by a larger average thermal-
displacement parameter (123Å2 vs. 109Å2 and 102Å2). Despite the lower resolution of the diffraction data, the same 
asparagine residues as in the zymogen plus position 592 showed evident N-linked glycosylations, which total 12 N-
acetylglucosamine, 9 #-D-mannose, 3 #-L-fucose, and 2 !-D-mannose moieties. Therefore, we assume that position 
592 is likewise glycosylated in the zymogen but that these sugars are flexible. All four cysteine pairs at adequate 
distance for disulfide bonding were built as disulfide bridges. Segment 300-310, which contains the C305–mediated 
intermolecular disulfide bond, was traced based on weak electron density and should be treated with caution. Extra 
electron density in the active-site cleft was conservatively interpreted as a glycerol molecule.  
Miscellaneous — Figures were prepared with program CHIMERA (11). Interaction surfaces (taken as half of 
the surface area buried at a complex interface) were calculated with CNS (12). Structure similarities were investigated 
with DALI (13). Model validation was performed with MOLPROBITY (14) and the WHATCHECK routine of 
WHATIF (15). To obtain a working model for the complete active dimer, a homology model for the EGF-like domain 
of M! (residues 606-647) was constructed with SWISS-MODEL (16) based on a receptor-binding region of Notch 
ligand (PDB entry 2VJ3; sequence identity 36%; E-value 7.6E-6). This model was connected with constructed models 
for the transmembrane helix (residues 653-673) and the cytosolic region (674-701), and with the experimental structure 
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by linkers of stereochemically reasonable conformation. A type-I transmembrane substrate was constructed based on 
the APP sequence (residues 624-723; UniProt P05067) and the solution structure of A!42 in high organic solvent 
(PDB 1IYT; (17)), keeping its helical conformation only for the transmembrane region. The final coordinates of the 
experimental structures of human pM!"C and M!"C have been deposited with the PDB at www.pdb.org (access 
codes XXXX and YYYY). 
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3. LEGENDS TO THE SUPPLEMENTARY FIGURES 
 
Supplementary Figure S1 —  (A) Ribbon-type plot of the constituting domains of pM!"C: PD+CD (ochre 
and aquamarine; left panel; shown in standard orientation according to (19)), MAM (red; middle panel), and TRAF 
(purple; right panel). The regular secondary structure elements are labeled (helices #1-#5, strands !1-!30, and 310-
helices $1-$3). The two ions present in the structure, zinc and sodium, are shown as magenta and blue spheres, 
respectively, as are the cysteine residues (!-"). The anchor points of the flexible activation domain are shown by 
black arrows, and scissors highlight the final maturation cleavage point.!(B) Topology scheme of the four domains of 
pM!"C as in (A). The regular secondary structure elements are depicted, labeled, and their terminal residues indicated. 
MAM (center) features two intercalated Greek-key motifs (in red and magenta, respectively) and additional elements in 
pink. TRAF (right) also consists of two intercalated Greek-key motifs (in lilac and purple, respectively) decorated with 
additional elements in blue. Cysteine residues are shown as yellow sticks and labeled in orange. The seven N-
glycosylation sites are also shown, with the corresponding asparagine residues labeled in blue. In each case, the most 
complete sugar structure found in any of the two zymogen molecules or the single mature-enzyme molecule present in 
the respective crystal asymmetric units is shown; a gray square represents N-acetylglucosamine, a circle #-D-mannose, 
a hexagon !-D-mannose, and a triangle #-L-fucose. See also Sup. Fig. S2. Dashed lines represent regions disordered in 
the zymogen structure. (C) Zinc-binding site environment, with distances: !, 2.24/2.33Å; #, 2.06/2.12Å; $, 
2.00/2.06Å; %, 1.96/1.96Å; and ", 2.13/2.22Å. (D) Sodium-binding site, with distances: !, 2.24/2.37Å; #, 
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2.47/2.54Å; $, 2.21/2.22Å; %, 2.43/2.47Å; ", 2.87/3.07Å; &, 2.67/2.74Å; and ', 2.51/2.63Å. The two values refer 
to the two molecules in the crystal asymmetric unit of pM!"C. Residue E268 is not fully defined by electron density. 
Supplementary Figure S2 — Scheme depicting the N-glycan patterns found in the structure of (p)M!. They 
are in accordance with glycans found in recombinant proteins produced in Trichoplusia ni insect cells (see Table 1 in 
(20)). NAG stands for N-acetylglucosamine, MAN for #-D-mannose, BMA for !-D-mannose, and FUC for #-L-
fucose. The respective type of glycosidic bond is further shown. 
Supplementary Figure S3 — (A) Superposition of the pM!"C dimer (ochre/aquamarine) onto the active 
M!"C dimer (red) in two orthogonal views. The ions correspond to those of the zymogen. (B) Superposition in stereo 
of the CDs of pM!"C (ochre/aquamarine) and M!"C (red) in standard orientation (19, 21). (C) Close-up view of (B) 
in stereo displaying the pM!"C structure and the residues mainly involved in rearrangement upon activation. The 
segments flanking the disordered activation segment are pinpointed by black arrows. (D) Same as (C) for the M!"C 
structure. 
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SUPPLEMENTARY TABLES 
Supplementary Table S1 — Crystallographic data. 
Dataset Pro-meprin ! "C Pro-Meprin ! "C (Zn2+-edge) Meprin !  "C (Zn2+-edge) 
Space group / cell constants (a, b, c, in Å; #, !, $ in º)  P1 / 69.62, 71.12, 85.74 P1 / 69.50,70.70,85.74  P6122 / 75.0, 75.0, 502.7 
 74.87, 80.08, 65.13 74.78, 80.14, 65.25 90.0, 90.0, 120.0!
Wavelength (Å) 0.9763 1.2815 1.2818  
No. of measurements / unique reflections 455,032  /  118,474 351,637  /  91,459 398,689  /  18,106  
Resolution range (Å) (outermost shell) a 48.45 – 1.85 (1.95 – 1.85) 48.5 – 2.00 (2.11 – 2.00) 48.2 – 3.00 (3.16 – 3.00)  
Completeness / Anomalous completeness (%) 96.6 (95.6) / - 94.7 (93.3) / 89.8 (89.7) d 99.9 (99.3) / - 
Rmerge b 0.069 (0.827) 0.055 (0.494) 
d 0.106 (0.912) 
Rr.i.m. (= Rmeas) b / Rp.i.m.  b 0.080 (0.959)  /  0.041 (0.485) 0.078 (0.699)  /  0.055 (0.494) 
d 0.108 (0.932)  /  0.022 (0.189)  
Average intensity (<[<I> / %(<I>)]>) 16.6 (2.3) 22.9 (3.4)  22.0 (22.9)  
B-Factor (Wilson) (Å2) / Average multiplicity 25.2  /  3.8 (3.9) 27.0  /  3.8 (3.8)  92.2  /  25.1 (3.5)  
Resolution range used for refinement (Å) ! – 1.85  ! – 3.00 
No. of reflections used (test set) 118,473 (1,124)  17,972 (711) 
Crystallographic Rfactor (free Rfactor) b 0.168 (0.188)  0.196 (0.238) 
No. of protein atoms / solvent molecules / ions 8,966  /  808 / 2 Zn2+, 2 Na+, 5 Cl-  4,271  /  - / 1 Cd2+, 1 Na+ 
     sugar moieties / ligands 20 NAG, 21 MAN, 8 FUC/ 1 GOL   12 NAG, 11 MAN, 3 FUC/ 1 GOL 
Rmsd from target values  
      bonds (Å)  /  angles (°) 0.010  /  0.99  0.008  /  0.98 
Aver. B-factors protein / sugars+ligands+waters / ions (Å2) 37.1 / 54.9 / 25.8  110.8 / 146.0 / 104.9 
Residue main-chain conformational angle and side-chain rotamer analysis c 
      favored regions / outliers / all residues / bad rotamers   1,080 / 1 / 1,101 / 2.7%  505 / 1 / 531 / 4.7% 
a   Values in parentheses refer to the outermost resolution shell. b   For definitions, see Table 1 in (18).  
c   According to MOLPROBITY (14).d   Friedel pair were treated separately. 
NAG, N-acetyl glucosamine; MAN, #- or !-mannose; FUC, fucose; GOL, glycerol. 
 
